Evidence map›Paper›PMID 34274492›Full record

ArticleTransplantation and cellular therapy2021

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Haris Ali, Dat Ngo, Ahmed Aribi, Shukaib Arslan, Sanjeet Dadwal, Guido Marcucci, Ryotaro Nakamura, Stephen J Forman, Jason Chen, Monzr M Al Malki

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 6 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 6 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California. Electronic address: harisali@coh.org.
Dat NgoDepartment of Pharmacy, City of Hope, Duarte, California.
Ahmed AribiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Shukaib ArslanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Sanjeet DadwalDepartment of Infectious Diseases, City of Hope, Duarte, California.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Jason ChenDepartment of Pharmacy, City of Hope, Duarte, California.
Monzr M Al MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
City of Hope · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety and efficacy of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) emergency-use authorized (EUA) vaccines have been confirmed in the general population. However, there are no data on its safety and tolerability or efficacy in recipients of allogeneic hematopoietic stem cell transplant (HCT). We performed this study to identify the incidence of adverse events following SARS-CoV2 EUA vaccines, the incidence of new-onset graft-versus-host disease (GVHD) or worsening of existing GVHD after EUA vaccine administration, and the incidence SARS-CoV2 positivity in vaccinated HCT patients. We retrospectively reviewed 113 HCT patients who received at least one dose of EUA vaccine to describe the safety and tolerability, any impact on GVHD, and the incidence of SARS-CoV2 PCR positivity after vaccination. Patients received either Pfizer (BNT162b2) or Moderna (mRNA-1273) vaccines. Patients were included if they were 18 years or older and had received at least one dose of vaccine in the post-HCT setting. Most patients presented with myalgias/arthralgias (first dose, 7.7%; second dose, 14.6%), fatigue (first dose, 15.4%; second dose, 29.2%), and injection site pain (first dose, 40.4%; second dose, 43.8%). Other side-effects experienced by patients included nausea, vomiting, diarrhea, headache, and injection-site rash and swelling. Liver function abnormalities occurred in 18.6% of patients. Neutropenia, thrombocytopenia, and lymphopenia occurred in 13.3%, 11.5%, and 8.8% of patients, respectively. Forty percent of patients had active chronic GVHD at the time of vaccination, and worsening chronic GVHD occurred in 3.5% of the patients. New chronic GVHD developed in 9.7% of patients after vaccination. The SARS-CoV2 EUA vaccines were well tolerated in allogeneic HCT recipients.

Indexed as

COVID-19Hematopoietic Stem Cell TransplantationVaccinesBNT162 VaccineCOVID-19 VaccinesHumansRetrospective StudiesRNA, ViralSARS-CoV-2BNT162 VaccineCOVID-19 VaccinesRNA, ViralVaccinesAllogeneic hematopoietic stem cell transplantationBNT162b2COVID-19 vaccineGraft-versus-host diseasemRNA-1273Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2)

Identifiers

PMID34274492
PMCPMC8280601
OpenAlexW3179770364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.